Chia Tai Enterprises International Limited (3839.HK)
HKD 1.6
(-3.03%)
HKD 1.6
(-3.03%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 173.97 Million USD | 9.26% |
| 2022 | 159.23 Million USD | 11.82% |
| 2021 | 142.4 Million USD | 52.18% |
| 2020 | 93.57 Million USD | -10.91% |
| 2019 | 105.04 Million USD | 12.51% |
| 2018 | 93.36 Million USD | 25.38% |
| 2017 | 74.46 Million USD | -14.68% |
| 2016 | 87.27 Million USD | -14.24% |
| 2015 | 101.76 Million USD | -13.12% |
| 2014 | 117.13 Million USD | -4.16% |
| 2013 | 122.21 Million USD | -7.6% |
| 2012 | 132.27 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 54.65 Million USD | 4.19% |
| 2024 Q2 | 53.32 Million USD | -2.43% |
| 2023 Q2 | 39.3 Million USD | -9.64% |
| 2023 Q4 | 52.45 Million USD | 35.49% |
| 2023 FY | 173.97 Million USD | 9.26% |
| 2023 Q3 | 38.71 Million USD | -1.51% |
| 2023 Q1 | 43.5 Million USD | 18.87% |
| 2022 FY | 159.23 Million USD | 11.82% |
| 2022 Q3 | 41.43 Million USD | -1.56% |
| 2022 Q4 | 36.59 Million USD | -11.67% |
| 2022 Q1 | 39.12 Million USD | -10.73% |
| 2022 Q2 | 42.08 Million USD | 7.58% |
| 2021 Q1 | 35.77 Million USD | 51.34% |
| 2021 FY | 142.4 Million USD | 52.18% |
| 2021 Q4 | 43.82 Million USD | 24.45% |
| 2021 Q3 | 35.21 Million USD | 27.6% |
| 2021 Q2 | 27.59 Million USD | -22.85% |
| 2020 Q2 | 21.13 Million USD | -17.78% |
| 2020 Q4 | 23.63 Million USD | 2.28% |
| 2020 Q3 | 23.11 Million USD | 9.38% |
| 2020 FY | 93.57 Million USD | -10.91% |
| 2020 Q1 | 25.69 Million USD | -13.56% |
| 2019 Q2 | 24.78 Million USD | -3.35% |
| 2019 Q1 | 25.63 Million USD | -9.79% |
| 2019 FY | 105.04 Million USD | 12.51% |
| 2019 Q4 | 29.72 Million USD | 19.43% |
| 2019 Q3 | 24.89 Million USD | 0.45% |
| 2018 Q4 | 28.42 Million USD | 27.0% |
| 2018 Q2 | 18.67 Million USD | -21.81% |
| 2018 Q1 | 23.88 Million USD | -7.16% |
| 2018 FY | 93.36 Million USD | 25.38% |
| 2018 Q3 | 22.38 Million USD | 19.83% |
| 2017 Q4 | 25.72 Million USD | 41.35% |
| 2017 Q2 | 12.8 Million USD | -27.81% |
| 2017 Q1 | 17.73 Million USD | -30.34% |
| 2017 FY | 74.46 Million USD | -14.68% |
| 2017 Q3 | 18.2 Million USD | 42.14% |
| 2016 Q3 | 20.66 Million USD | -5.67% |
| 2016 Q2 | 21.9 Million USD | 13.78% |
| 2016 Q1 | 19.25 Million USD | -22.96% |
| 2016 Q4 | 25.45 Million USD | 23.22% |
| 2016 FY | 87.27 Million USD | -14.24% |
| 2015 FY | 101.76 Million USD | -13.12% |
| 2015 Q4 | 24.98 Million USD | -3.27% |
| 2015 Q3 | 25.83 Million USD | 2.38% |
| 2015 Q2 | 25.23 Million USD | -1.88% |
| 2015 Q1 | 25.71 Million USD | -21.54% |
| 2014 Q4 | 32.77 Million USD | 11.66% |
| 2014 Q3 | 29.35 Million USD | 6.74% |
| 2014 Q2 | 27.5 Million USD | 0.0% |
| 2014 Q1 | 27.5 Million USD | 0.0% |
| 2014 FY | 117.13 Million USD | -4.16% |
| 2013 FY | 122.21 Million USD | -7.6% |
| 2012 FY | 132.27 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | 32.868% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 98.348% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -194.391% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | 77.805% |
| Qianhai Health Holdings Limited | 961.29 Million HKD | 81.902% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 83.478% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 89.805% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | 78.497% |
| PuraPharm Corporation Limited | 406.85 Million HKD | 57.239% |
| SSY Group Limited | 6.46 Billion HKD | 97.308% |
| JBM (Healthcare) Limited | 648.41 Million HKD | 73.169% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 88.147% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.936% |